Compare CWT & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CWT | PGEN |
|---|---|---|
| Founded | 1926 | 1998 |
| Country | United States | United States |
| Employees | 1105 | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.8B |
| IPO Year | 1997 | 2013 |
| Metric | CWT | PGEN |
|---|---|---|
| Price | $47.93 | $6.20 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $53.75 | $13.65 |
| AVG Volume (30 Days) | 358.3K | ★ 4.6M |
| Earning Date | 10-29-2026 | 11-12-2026 |
| Dividend Yield | ★ 2.82% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.01 | 0.03 |
| Revenue | ★ $963,695,000.00 | $230,981,000.00 |
| Revenue This Year | $9.24 | $2,365.68 |
| Revenue Next Year | $6.80 | $85.75 |
| P/E Ratio | ★ $47.10 | $212.83 |
| Revenue Growth | ★ 6.41 | N/A |
| 52 Week Low | $41.29 | $3.04 |
| 52 Week High | $53.82 | $8.98 |
| Indicator | CWT | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 59.64 | 34.75 |
| Support Level | $42.84 | $6.08 |
| Resistance Level | $48.10 | $7.30 |
| Average True Range (ATR) | 1.17 | 0.38 |
| MACD | 0.34 | -0.18 |
| Stochastic Oscillator | 90.35 | 2.57 |
California Water Service Group is a U.S. water and utilities holding company based in California. The company provides water utility and other related services in California, Washington, New Mexico, Hawaii and Texas through its wholly-owned subsidiaries. The bulk of the company's business consists of the production, purchase, storage, treatment, testing, distribution, and sale of water for domestic, industrial, public, and irrigation uses, and the provision of water for domestic and municipal fire protection services.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.